Table 2.

Univariate analysis of clinical factors and GPS for overall survival (n = 402)

	Patients (%)	mOS months (95% CI)	P-value
Age
<60	203 (50.5)	11.6 (10.1-13.2)	0.808
≥ 60	199 (49.5)	12.0 (9.9-14.1)
Gender
Male	293 (72.9)	11.7 (10.1-13.3)	0.952
Female	109 (27.1)	12.1 (10.6-13.6)
Liver Mets
Yes	125 (31.1)	11.4 (8.5-14.3)	0.352
No	277 (68.9)	12.0 (10.7-13.3)
Peritoneal Mets
Yes	159 (39.6)	9.9 (8.4-11.5)	0.023
No	243 (60.4)	13.0 (11.2-14.8)
Bone Mets
Yes	28 (7.0)	8.2 (7.1-9.3)	0.117
No	374 (93.0)	12.1 (10.9-13.2)
Albumin
<3.5	77 (19.2)	7.7 (5.9-9.5)	0.001
≥ 3.5	325 (80.8)	12.4 (10.7-14.2)
CRP
≤ 1	262 (64.9)	14.8 (12.7-17.0)	0.001
>1	140 (34.8)	8.7 (7.3-10.2)
ECOG PS
0-1	329 (81.8)	12.4 (10.9-13.8)	0.003
≥ 2	73 (48.2)	8.7 (7.3-10.0)
GPS
0	238 (59.2)	15.3 (13.1-17.5)	0.001
1	111 (27.6)	8.9 (7.2-10.7)
2	53 (13.2)	7.6 (4.9-10.2)

mOS: median overall survival, Mets: metastasis, CRP: C-reactive protein, ECOG PS: Eastern Cooperative Oncology Group, performance status, GPS: Glascow prognostic score